ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
May 16 2022 - 8:30AM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health-solutions company, today announced that it will report its
financial results for the first quarter ended March 31, 2022,
including a corporate update, on Monday, May 23, 2022, pre-market.
Management will post a webcast at 8:30 am ET. A
link to the webcast will be available on the “Events and
Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations.
An archived replay will also be available on the
“Events and Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences™
ReShape Lifesciences™ is America's premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
Program provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™
System is an investigational (outside the U.S.) minimally invasive,
laparoscopically implanted medical device that wraps around the
stomach, emulating the gastric volume reduction effect of
conventional weight-loss surgery. It helps enable rapid weight loss
in obese and morbidly obese patients without permanently changing
patient anatomy. reshapecare™ is a virtual
weight-management program that supports lifestyle changes for all
weight-loss patients led by board certified health coaches to help
them keep the weight off over time. The recently launched ReShape
Marketplace™ is an online collection of quality wellness products
curated for all consumers to help them achieve their health goals.
For more information, please visit www.reshapelifesciences.com.
CONTACTS:
Company
Contact: Thomas
StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Sep 2023 to Sep 2024